Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2014 1
2015 1
2016 1
2017 2
2019 4
2020 5
2021 5
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: namikawa m. Intern Med. 2021;60(19):3061-3070. doi: 10.2169/internalmedicine.6591-20. Epub 2021 Oct 1. Intern Med. 2021. PMID: 34602520 Free PMC article.
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T, Naganuma A, Shibasaki M, Kohga T, Arai Y, Nagashima T, Ueno T, Namikawa M, Saito S, Hoshino T, Takizawa D, Arai H, Makita F, Kakizaki S, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: namikawa m. Oncology. 2021;99(4):203-214. doi: 10.1159/000511734. Epub 2020 Dec 4. Oncology. 2021. PMID: 33279908
Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.
Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Takaoka Y, et al. Among authors: namikawa m. Hepatol Res. 2021 Jan;51(1):51-61. doi: 10.1111/hepr.13576. Epub 2020 Oct 20. Hepatol Res. 2021. PMID: 33021009
Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015.
Yamazaki Y, Naganuma A, Arai Y, Takeuchi S, Kobayashi T, Takakusagi S, Hatanaka T, Hoshino T, Namikawa M, Hashizume H, Takizawa D, Ohyama T, Suzuki H, Horiguchi N, Takagi H, Sato K, Kakizaki S, Kusano M, Nagashima S, Takahashi M, Okamoto H, Yamada M. Yamazaki Y, et al. Among authors: namikawa m. Hepatol Res. 2017 Apr;47(5):435-445. doi: 10.1111/hepr.12765. Epub 2016 Jul 27. Hepatol Res. 2017. PMID: 27322051
Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: namikawa m. Hepatol Res. 2020 Mar;50(3):303-312. doi: 10.1111/hepr.13462. Epub 2019 Dec 19. Hepatol Res. 2020. PMID: 31750974
Full-length genomic sequences of new subtype 1g hepatitis E virus strains obtained from four patients with imported or autochthonous acute hepatitis E in Japan.
Nishizawa T, Primadharsini PP, Namikawa M, Yamazaki Y, Uraki S, Okano H, Horiike S, Nakano T, Takaki S, Kawakami M, Nagashima S, Takahashi M, Okamoto H. Nishizawa T, et al. Among authors: namikawa m. Infect Genet Evol. 2017 Nov;55:343-349. doi: 10.1016/j.meegid.2017.10.007. Epub 2017 Oct 5. Infect Genet Evol. 2017. PMID: 28987806
15 results